• Facebook
  • Twitter
  • LinkedIn
  • Youtube
  • Mail
  • For Patients
  • Customer Login
  • Newsletter Sign-up
Profound Medical
  • Home
  • News
    • Events
  • Physicians
    • Customizable Incision-Free Therapies
  • Technology
    • TULSA-PRO®
    • Sonalleve®
  • Company
    • About
    • Leadership Team
    • Board of Directors
    • Careers
    • Clinical Publications
  • Investors
    • Profile
    • Governance
    • Presentations
    • TACT Data
    • Webcasts
    • Financial
    • Press Releases
    • Analyst Coverage
    • Subscribe
  • Contact
  • Menu Menu

The TULSA-PRO® System Featured on the Cover of The Journal of Urology

We are delighted to share that the TULSA-PRO® system was featured on the March 2021 cover of The Journal of Urology

The TULSA-PRO® system delivers precise thermal ablation of a physician prescribed region of prostate tissue, by combining real-time MR imaging, with transurethral directional ultrasound and closed-loop process control software.

One of the most widely read and highly cited journal in the field of urology, The Journal of Urology® is a peer-reviewed journal bringing the most relevant and up-to-date urological learnings and ground-breaking research from premier industry sources.  This is the official journal of the American Urological Association (AUA), which Profound Medical is excited to have the TULSA-PRO® system featured in.

Below is the Abstract from The Journal of Urology®

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer 

Purpose:

Magnetic resonance imaging-guided transurethral ultrasound ablation uses directional thermal ultrasound under magnetic resonance imaging thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT).

Materials and Methods:

A total of 115 men with favorable to intermediate risk prostate cancer across 13 centers were treated with whole gland ablation sparing the urethra and apical sphincter. The co-primary 12-month endpoints were safety and efficacy.

Results:

In all, 72 (63%) had grade group 2 and 77 (67%) had NCCN® intermediate risk disease. Median treatment delivery time was 51 minutes with 98% (IQR 95–99) thermal coverage of target volume and spatial ablation precision of ±1.4 mm on magnetic resonance imaging thermometry. Grade 3 adverse events occurred in 9 (8%) men. The primary endpoint (U.S. Food and Drug Administration mandated) of prostate specific antigen reduction ≥75% was achieved in 110 of 115 (96%) with median prostate specific antigen reduction of 95% and nadir of 0.34 ng/ml. Median prostate volume decreased from 37 to 3 cc. Among 68 men with pretreatment grade group 2 disease, 52 (79%) were free of grade group 2 disease on 12-month biopsy. Of 111 men with 12-month biopsy data, 72 (65%) had no evidence of cancer. Erections (International Index of Erectile Function question 2 score 2 or greater) were maintained/regained in 69 of 92 (75%). Multivariate predictors of persistent grade group 2 at 12 months included intraprostatic calcifications at screening, suboptimal magnetic resonance imaging thermal coverage of target volume and a PI-RADS™ 3 or greater lesion at 12-month magnetic resonance imaging (p <0.05).

Conclusions:

The TACT study of magnetic resonance imaging-guided transurethral ultrasound whole gland ablation in men with localized prostate cancer demonstrated effective tissue ablation and prostate specific antigen reduction with low rates of toxicity and residual disease.

See full article

Contact Profound Medical to learn more
Share:
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail

Recent Posts

  • AUA Happy Hour
  • How did you hear about us
  • (no title)
  • SONALLEVE WEBINAR: March 30th 2022
  • Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

Categories

  • Blog Post
  • CEO Update
  • Events
  • Frontpage Article
  • News
  • Uncategorized
  • Whitepapers

Tags

CEO Message CONALLEVE Corona Corona Virus COVID-19 Erectile Dysfunction Erectile Function EUROPE FLA HIFU meeting PATIENT PROFOUND PROSTATE RELEASE SOFTWARE SONALLEVE TACT TDC tulsa TULSA-PRO TULSAPRO tulsa procedure TULSAPROCEDURE TULSA TREATMENT Webinar

News

AUA Happy Hour

April 19, 2022
Read more
https://profoundmedical.com/wp-content/uploads/2022/04/Profound-Happy-Hour-Invite_ad-scaled.jpg 1344 2560 Profound Medical https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Profound Medical2022-04-19 16:16:442022-04-20 17:19:49AUA Happy Hour

SONALLEVE WEBINAR: March 30th 2022

February 23, 2022
Read more
https://profoundmedical.com/wp-content/uploads/2022/02/2022.03.30_Sonalleve-Webinar_Web-Image-scaled.jpg 1344 2560 Profound Medical https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Profound Medical2022-02-23 11:38:422022-03-30 05:48:14SONALLEVE WEBINAR: March 30th 2022

Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

October 4, 2021
Read more
https://profoundmedical.com/wp-content/uploads/2021/09/ALTA-Study-Blog-Image.png 2550 3300 Profound Medical https://profoundmedical.com/wp-content/uploads/2019/07/RGB_PROFOUND_For-Website-01-01.png Profound Medical2021-10-04 00:00:582021-09-29 15:26:42Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA)

Careers & Training

  • Careers
  • Customer Login
  • TULSA-PRO Training

Head Office

Profound Medical Corp.,
2400 Skymark Avenue,
Unit #6, Mississauga, ON  L4W 5K5, Canada

T: 647.476.1350 
F:
 647.847.3739
info@profoundmedical.com

 
© Copyright - Profound Medical 2021
  • Home
  • Physicians
  • TULSA PRO
  • Patients
  • Company
  • News
  • Investors
  • Contact
  • Customer Login
  • TULSA-PRO Training
  • Privacy Policy
TULSA-PRO WEBINAR: April 1st 2021SONALLEVE WEBINAR: May 12th 2021
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn More

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only